Index

Compiled by Linda English

Aberdeen children’s cohort study 16
abuse 80, 92, 302–303
Adult Asperger Assessment (AAA) 168
Adults with Incapacity Act (Scotland) 2000: 299
aetiology
  behavioural phenotypes and 22–24
  DID 16–19, 22–24
  psychiatric disorder 45–49
  ‘two-group’ perspective 16–17
affective disorders see mood disorders
ageing see elderly people
aggression 34, 77, 82, 84, 89, 187–188
agomelatine 65
alkaptonuria 6
alpha-2 adrenergic agonists 189
Alzheimer’s disease 18, 241, 271
amantadine 183, 189–190
American Association on Intellectual and Developmental Disabilities revised
  Adaptive Behavior Scale 11
Angelman syndrome 29, 34, 77
antidepressants 293
  anxiety disorders 65
  ASD 182, 184–186, 191
  behaviour problems 136, 137
  in children 283
anti-epileptics 120, 122, 123–125, 149, 191
antipsychotics 293
  ASD 182, 185, 187, 188, 190
  behaviour problems 77, 80, 137
  epilepsy 118, 123
  OCD 65–66
anxiety disorders 58–71
aetiology 63–64
  ASD 136, 169, 186, 191, 218–224
  behavioural correlates 62
  behaviour problems 62, 64–65, 96
  in children 283
  classification 60–61
diagnosis 60–61
environmental influences 64
epidemiology 43, 58–59
fear 58
fragile-X syndrome 34
  genetic influences 63
neurobiological influences 63
pharmacological therapies 65–66
psychological influences 64
psychological therapy 65, 66–67
risk factors 64
treatment 65–67
Williams syndrome 18
applied behaviour analysis (ABA) 9, 18, 19, 281
ASD 9, 202–217, 225–226
augmentative and alternative communication (AAC) approaches 206
  behaviour problems 6, 73, 82, 209–210
  communication 204–206
  daily living 208–209
  discreet trial training (DTT) 205, 206
  key elements 204
  natural environment training (NET) 205–206
Picture Exchange Communication System (PECS) 206
  social skills 206–208
v. intensive behavioural intervention (IBI) 210
arbaclofen 28, 34, 194
aripiprazole 135, 182, 186, 187, 190
Asperger, Hans 159, 160
Asperger syndrome 147, 159–177, 189
Asperger Syndrome Diagnostic Interview (ASDI) 168
atomoxetine 189, 190
attachment: behaviour problems 89–90, 284
attention-deficit hyperactivity disorder (ADHD) 27
INDEX

ASD  153–154, 165, 168, 169, 188–190, 223
    behaviour problems  97, 100
    in children  280, 281
    genetics  26
Autism Diagnostic Instrument - Revised (ADI-R)  168
Autism Diagnostic Observation Scale (ADOS-2)  168
autism spectrum disorder (ASD)  5, 22, 147–235, 280, 281, 284
    activities of daily living training  208–209
    aetiology  148–150
    aggression  84, 187–188
    applied behavioural analysis  9, 202–217, 225–226
    Asperger syndrome  147, 159–177, 189
    assessment  164–168
    ‘autism epidemic’  163
    behavioural phenotypes and  22, 23
    behaviour problems  76, 82, 83, 89, 90, 92, 96–97, 100, 187–188, 209–210
    broader autism phenotype (BAP)  153
    CBT  202, 218–224, 225, 226
    classification  11, 150–153
    clinical specifiers  150–151, 154
    cognitive ability  165, 223, 224
    communication deficits  204–206, 210
    complexity of phenotype  153–154
    concepts and labels  159–162
    developmental cascade effects  152–153
    diagnosis  150–153, 164–168
    diagnostic instruments  166–168
    diet  182
    differential diagnoses  166
    Down syndrome  27
    environmental factors  148, 149–150
    epidemiology  147–148, 162–163, 178
    epilepsy  113, 117, 124–125, 163
    fixated interests and repetitive behaviours (FIRB)  151
    fragile-X syndrome  27, 28, 148
    functional ability  165, 208–209
    genetic causes  26, 148–149
    hyperkinesis/inattention  188–190
    intensive behavioural intervention  210–217, 225, 226
    legal issues  172–175
    medical problems  154, 165
    mental capacity  172
    National ASD Standards (NAS)  202
    NICE guidelines  179, 181, 182, 186, 190, 202
    nosology and clinical and research utility  155
    offending  163, 175
    ordinary life  171–172
    parental age  149–150
    parental involvement  216, 224
    placebo response  193
    presentation in adulthood  163–164
    psychological treatment  54, 201–235
    psychotropic medication  34, 178–200, 301
    Rasopathies  30
    reliability as witness  173–174
    risk factors  148–150
    rubella-induced  31
    self-injurious behaviour  76, 187–188, 209–210
    sleep disorders  192
    social communication deficits (SOCOM)  151
    social communication disorder (SCD)  151–152, 161, 162
    social deficits and medication  181–184
    social skills training  172, 206–208
    social support  172
    stereotypical and ritualistic/compulsive behaviour  184–186
    symptom severity  150–151
    thought disorder  192
    tic disorders/OCD  191–192
    Autism Spectrum Quotient (AQ)  168
    autoimmune aetiology  32–33
    behavioural phenotypes  19, 22–38, 120
    aetiology of psychiatric disorder  45–46
    autoimmunity  32–33
    definition  25–26
    genetic causes  18, 26–30
    infective causes  31–32
    novel interventions  34
    toxic causes  30–31
    behavioural therapy  54, 82
    see also applied behavioural analysis (ABA)
    behaviour problems  6, 52, 72–112
    abuse  92
    aggression  34, 77, 82, 84, 89, 187–188
    anxiety disorders  62, 64–65, 96
    ASD  76, 82, 83, 89, 90, 92, 96–97, 100, 209–210
    assessment  50, 73, 80–81, 96, 131–132, 133
    attachment  89–90
    barriers to healthcare  243
INDEX

behavioural approaches 82
behavioural phenotypes 22, 23, 34
in children 281, 282, 284
communication 81, 84, 90–91, 134
crisis services 84
diagnostic criteria 96–97
distress behaviours 72, 74, 89, 95
eternal milieu 82
environments and supports 73, 80–84, 101
epidemiology 43
epilepsy 120
forensic psychiatry 297–298, 299–300
in genetic syndromes 22, 76–77
HELP framework 73–100
individual needs 80–81
life events 91–92
medical conditions 74, 75, 101
mental state examination 96, 101
missed and problematic diagnoses 97
multiple diagnoses 97–100
neglect 92
neurobiology 92–95
pain 75–76
physical environment 82–83
physical exercise 83
positive behavioural support 9, 82, 299–300
psychiatric disorder 73, 95–100, 101, 130
self-injurious behaviour 72, 76, 77, 82, 89, 96
Snoezelen rooms 83
socially unacceptable behaviours 72, 73, 80, 130
social relationships and networks 91
somatic conditions 97
specialist services 84
staff and carer provider supports 83–84
stress 89
traumatic experiences 91–92, 97
see also psychotropic medication for
behaviour problems
Being a General Practitioner 257
benzodiazepines 65–66, 118, 283
bereavement 92
best interests 53
Better Services for the Mentally Handicapped 7–8
biomedical model: of disability 4, 5, 8, 11, 14, 15, 16
bipolar disorder 171, 191
birth trauma 115–116
BMPS model: assessment of problem
behaviours 139–141 (Appendix 1)
Books Beyond Words 53, 82, 96
capacity 259
ASD 53, 165, 172
forensic psychiatry 292, 299
surgery in epilepsy 125
cataracts: Down syndrome 266
catatonia 171
cerebral palsy 46, 90, 113
challenging behaviour see behaviour problems
channelopathies 116
children 277–290
aetiology of mental health problems 78–79
assessment 280–282
biological functions 282
comorbidities 279
developmental history 281
epidemiology of mental health problems
277–278
family history 281
future service development 288–289
in-patient care 288
investigations 282
medical history 282
physical examination 282
presenting complaint 281
psychiatric history 281
psychometric assessments 282
service needs 284–286
service provision 284–289
social history 281–282
social support 48–49
specialist (tiers 3 and 4) services 286, 287–288
targeted (tier 2) services 286, 287
transition services 285–286
treatment 283–284
universal (tier 1) services 286–287
vulnerability 279–280
Children’s Act 2004: 286
cholinergics 189
chromosome 15: 18, 29
classification of DID 9–15
classification systems, multi-axial 24
clinical–phenomenological diagnoses 22–24
cognitive–behavioural therapy (CBT) 54
anxiety disorders 66
ASD 202, 218–224, 225, 226
children 284
epilepsy 125
communication
ASD 204–206, 210
behaviour problems 81, 84, 90–91, 134
healthcare barrier 243
non-verbal 81, 134, 162

© in this web service Cambridge University Press www.cambridge.org
INDEX

within/between teams and with carers 258–259
comorbidity 41–144
congenital heart disease: Down syndrome 267
congenital rubella 8, 31
counsel 53, 125, 130, 134, 259
coping strategies 47, 89, 90, 92
copy number variants (CNVs) 10, 17, 116, 149–150, 168
Cornelia de Lange syndrome 22, 52, 64, 76–77, 120
D-cycloserine 183
cytomegalovirus (CMV) 31–32

dangerous and severe personality disorder programme 294
Death by Indifference 240
DECIPHER database 17
deletion syndromes 17
dementia 265–266, 267–275
Alzheimer’s disease 18, 241, 271
classification 270–272
cortical 270, 271–272
diagnostic criteria 269–270
Down syndrome 18, 265–266, 269, 275
epidemiology 268–269
investigation 272–273
mixed 270, 272
natural history 273–275
‘possible’ 270
schedules 270
subcortical 270, 272
de prerogativa regis 292
depression 247
anxiety disorders 60
ASD 171, 186, 190–191
in children 280, 283
coping style 47
Down syndrome 27, 45, 267, 268
elderly people 268
epilepsy 117
social support 48
developmental trajectories 5, 19, 152
diagnosis
behavioural phenotypes and 22–24
diagnostic instruments 50–52
diagnostic overshadowing 52, 60, 186, 218
EASTER CARE acronym 261
of psychiatric disorder 52–53
Diagnostic Criteria for Psychiatric Disorders for Use with Adults with Learning Disabilities/Mental Retardation (DC-LD) 52, 61, 96–97, 132
Diagnostic Instrument for Social and Communication Disorders (DISCO) 168
Diagnostic Interview Guide 168
Diagnostic Manual - Intellectual Disability (DM-ID) 52, 61, 96
Diagnostic and Statistical Manual of Mental Disorders (DSM) 11–12, 97, 159
DSM-III 159
DSM-IV 43, 52, 161, 162
DSM-IV-TR 60–61, 201
DSM-5: 3, 9, 11–12, 58, 96, 147, 150–152, 159, 161, 178, 249–251, 269
disability 14
biomedical model 4, 5, 8, 11, 14, 15, 16
identification and benefits 251–255
psychiatric illness increases with severity 43
social model 4, 5, 7, 8, 14, 15, 277
systemic model 4, 5–6
Disability Discrimination Act 2005: 284
DNA expansion 29
microdeletion 29
sequencing 6
structure 6
Down syndrome 292
ageing 265–268, 269, 275
attachment 90
behavioural phenotype 26–27
cataracts 266
congenital heart disease 267
dementia 18, 265–266, 269, 275
depression 45, 267, 268
epilepsy 116–117
health needs 242
hypothyroidism 266–267, 282
infections 267
life expectancy 241
muscle hypotonia and joint laxity 267
terminology 251
trisomy 21: 6, 17, 26
dual diagnosis 41–57

Early Start Denver Model (ESDM) 211–212
EASTER CARE acronym 261
education
of doctors 260–261
education authorities requirement to provide 7
elderly people 264–276
dementia 265–266, 267–275
depression 267, 268
Down syndrome 265–273, 275
epilepsy 267–268
INDEX

health screening  265, 266–268
increasing longevity  264–265
syndrome-specific screening  266–268
treatable morbidity  265–268
Emergency Care Summary  258
emergency department visits: ‘triggers’  260
Empathy Questionnaire (EQ)  168
epigeneotics  6
epilepsy  113–129
aetiology  115–116
anti-epileptic medication  120, 121, 122,
123–125
ASD  113, 117, 124–125, 163
assessment  121–123
association with DID  116–117
behaviour disorders  120
in children  284
classification  114
cognitive function  120–121
diagnosis  121–123
EEG  122, 243
epilepsy  267–268
epimediology  113–114
focal seizures  114
‘forced normalisation’ and psychosis  119
generalised seizures  114
health improvement  241–242, 243, 247
immagneediated syndromes  120
International League Against Epilepsy  114
mood disorders  117
neuroimaging  123
neuropsychiatric manifestations  46,
117–121, 126
neuropsychological testing  122–123
non-pharmacological management  125
pharmacological management  123–125, 126
psychological interventions  125
psychosis  118–120
service issues  126
surgery  125
temporal lobe  46, 118, 119, 121
teratogenic risks of anti-epileptic agents
124–125
tonic–clonic seizures  120, 121
vagus nerve stimulation  125
video-recording  122
Equality Act 2010:  284
eugenics movement  7, 296
exercise therapy  67, 83

fluorescent in situ hybridisation  29
fluoxetine  184, 194
fluvoxamine  184
Forensic Care Pathways for Adults with
Intellectual Disability Involved with the
Criminal Justice System  291–292
forensic psychiatry  291–304
‘administrative detention’  294, 298
anger  300–301
ASD  163
capacity  291, 292, 299
community forensic DID teams  303
fitness to plead  299
historical and philosophical issues  292–298
hospital treatment  300–302
models of care  299–300
outcome-based research  303–304
prison population  294–295
risk assessment/management  293, 301
sex offending  300, 301
suggestibility  298
what DID is  295–298
what forensic psychiatry is  293–295
what psychiatry is  292–293
Winterbourne View  302–303
formulation  3
fragile-X mental retardation protein (FMRP)  27
fragile-X syndrome  18, 24, 27–28
ASD  27, 28, 148
epilepsy  116
epilepsy  116
genetics  10, 17, 27, 29
medical conditions  242
novel medication  34
self-injury  76, 77
social anxiety  45–46, 64
fragile-X tremor–ataxia syndrome
(FRAXTAS)  28
functional communication training (FCT)
81, 210

GABA agonists  28, 34, 194
gender  26, 148, 280
generalised anxiety disorder (GAD)  63, 66
general practitioners see primary care
genetics  16–18
ASD  26, 148–149, 195
genetic counselling  24–25
genotypic approach  26
history of  6
knockout mouse models  18–19
microdeletion syndromes  29
parental inheritance and imprinting  29–30
<table>
<thead>
<tr>
<th>Index</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>genetic syndromes 5, 18</td>
<td></td>
</tr>
<tr>
<td>ageing 265</td>
<td></td>
</tr>
<tr>
<td>behavioural phenotypes 26–30, 45–46</td>
<td></td>
</tr>
<tr>
<td>behaviour problems 76–77</td>
<td></td>
</tr>
<tr>
<td>in children 280, 281</td>
<td></td>
</tr>
<tr>
<td>epilepsy 113, 116–117, 120</td>
<td></td>
</tr>
<tr>
<td>glutamate antagonists 28, 34</td>
<td></td>
</tr>
<tr>
<td>guardianship 19, 29</td>
<td></td>
</tr>
<tr>
<td>handicap 14</td>
<td></td>
</tr>
<tr>
<td>health improvement 239–248</td>
<td></td>
</tr>
<tr>
<td>barriers to healthcare 242–244, 252</td>
<td></td>
</tr>
<tr>
<td>behaviour problems 243</td>
<td></td>
</tr>
<tr>
<td>communication 243</td>
<td></td>
</tr>
<tr>
<td>epilepsy 241–242</td>
<td></td>
</tr>
<tr>
<td>health disparity 239–241, 244–247</td>
<td></td>
</tr>
<tr>
<td>health needs 241–242, 244, 252–253</td>
<td></td>
</tr>
<tr>
<td>mobility 242</td>
<td></td>
</tr>
<tr>
<td>mortality 242, 265</td>
<td></td>
</tr>
<tr>
<td>primary care 244–246</td>
<td></td>
</tr>
<tr>
<td>sensory deficit 241, 242–243</td>
<td></td>
</tr>
<tr>
<td>specialist psychiatric care 243–244, 246–247</td>
<td></td>
</tr>
<tr>
<td>syndrome-specific conditions 242</td>
<td></td>
</tr>
<tr>
<td>health screening</td>
<td></td>
</tr>
<tr>
<td>elderly people 265, 266–268</td>
<td></td>
</tr>
<tr>
<td>primary care 245, 255–256, 259</td>
<td></td>
</tr>
<tr>
<td>Healthy Child Programme (HCP) 286–287</td>
<td></td>
</tr>
<tr>
<td>hearing impairment 241</td>
<td></td>
</tr>
<tr>
<td>HELP framework for behaviour problems 73–100</td>
<td></td>
</tr>
<tr>
<td>environments and supports 80–84</td>
<td></td>
</tr>
<tr>
<td>health 74–80</td>
<td></td>
</tr>
<tr>
<td>lived experience and emotional well-being 89–95</td>
<td></td>
</tr>
<tr>
<td>psychiatric concerns 95–100</td>
<td></td>
</tr>
<tr>
<td>Hippocrates 292</td>
<td></td>
</tr>
<tr>
<td>historical background 6–8</td>
<td></td>
</tr>
<tr>
<td>hospitals, acute 259–260</td>
<td></td>
</tr>
<tr>
<td>human genome 6</td>
<td></td>
</tr>
<tr>
<td>hypothyroidism: Down syndrome 266–267, 282</td>
<td></td>
</tr>
<tr>
<td>Immediate Discharge Document 258</td>
<td></td>
</tr>
<tr>
<td>immunomodulatory agents 33, 182</td>
<td></td>
</tr>
<tr>
<td>impairment 5, 13–14</td>
<td></td>
</tr>
<tr>
<td>imprinting 29–30</td>
<td></td>
</tr>
<tr>
<td>Increased Access to Psychological Therapies (IAPT) Programme 288–289</td>
<td></td>
</tr>
<tr>
<td>independent sector 288, 291, 302–303</td>
<td></td>
</tr>
<tr>
<td>infections 17</td>
<td></td>
</tr>
<tr>
<td>behavioural phenotypes 25–26, 31–32</td>
<td></td>
</tr>
<tr>
<td>Down syndrome 267</td>
<td></td>
</tr>
<tr>
<td>epilepsy 115–116</td>
<td></td>
</tr>
<tr>
<td>intellectual developmental disorders (IDD) 11–12</td>
<td></td>
</tr>
<tr>
<td>intensive behavioural intervention (IBI): ASD 210–217, 225, 226</td>
<td></td>
</tr>
<tr>
<td>Intensive Interaction 81, 82, 90, 91</td>
<td></td>
</tr>
<tr>
<td>Intensive Therapy for Attachment and Behaviour (ITAB) 82, 90–91</td>
<td></td>
</tr>
<tr>
<td>International Classification of Diseases (ICD) 11–12, 96–97, 159</td>
<td></td>
</tr>
<tr>
<td>ICD-9: 159</td>
<td></td>
</tr>
<tr>
<td>ICD-10: 52, 60–61, 96, 150, 161, 162, 269, 270, 297</td>
<td></td>
</tr>
<tr>
<td>ICD-11: 3, 9, 11</td>
<td></td>
</tr>
<tr>
<td>International Classification of Functioning, Disability and Health (ICF) 14–15, 52–53</td>
<td></td>
</tr>
<tr>
<td>International Classification of Impairments, Disabilities and Handicaps 12–14</td>
<td></td>
</tr>
<tr>
<td>iodine deficiency, maternal 5, 17</td>
<td></td>
</tr>
<tr>
<td>IQ 10, 11, 16–17</td>
<td></td>
</tr>
<tr>
<td>Down syndrome 26</td>
<td></td>
</tr>
<tr>
<td>fetal alcohol spectrum disorders 30–31</td>
<td></td>
</tr>
<tr>
<td>Flynn effect 296</td>
<td></td>
</tr>
<tr>
<td>graph 295–296</td>
<td></td>
</tr>
<tr>
<td>law of regression to the mean 296</td>
<td></td>
</tr>
<tr>
<td>mild intellectual disability 7, 297 tests 6–7, 295–296</td>
<td></td>
</tr>
<tr>
<td>Isle of Wight study 22, 42</td>
<td></td>
</tr>
<tr>
<td>Kanner, Leo 147, 159</td>
<td></td>
</tr>
<tr>
<td>Klinefelter (XXY) syndrome 29</td>
<td></td>
</tr>
<tr>
<td>knockout mouse models 18–19</td>
<td></td>
</tr>
<tr>
<td>Lesch–Nyhan syndrome 18, 22, 25, 45, 52</td>
<td></td>
</tr>
<tr>
<td>Lewy body dementia 272</td>
<td></td>
</tr>
<tr>
<td>life events 48, 49, 64, 91–92, 280, 284</td>
<td></td>
</tr>
<tr>
<td>life expectancy 241, 242, 264–265</td>
<td></td>
</tr>
<tr>
<td>lithium 34, 136, 191</td>
<td></td>
</tr>
<tr>
<td>Lowe syndrome 76, 77</td>
<td></td>
</tr>
<tr>
<td>medical conditions see physical illness</td>
<td></td>
</tr>
<tr>
<td>medical students’ education 260–261</td>
<td></td>
</tr>
<tr>
<td>medication see psychotropic medication</td>
<td></td>
</tr>
<tr>
<td>melatonin 192</td>
<td></td>
</tr>
<tr>
<td>memantine 183, 194–195</td>
<td></td>
</tr>
<tr>
<td>Mental Capacity Act 2005: 53, 134, 291, 299</td>
<td></td>
</tr>
<tr>
<td>Mental Deficiency Act 1913: 3, 9–10, 292</td>
<td></td>
</tr>
<tr>
<td>Mental Health Act 1983: 291, 295, 297</td>
<td></td>
</tr>
<tr>
<td>mental state examination 96, 101</td>
<td></td>
</tr>
<tr>
<td>metabotropic glutamate receptor 5 (mGluR5) pathway 28, 34</td>
<td></td>
</tr>
<tr>
<td>methylphenidate 189, 190, 283</td>
<td></td>
</tr>
</tbody>
</table>
INDEX

microarray technologies 17
microdeletion syndromes 29
mild intellectual disability 17
  anxiety disorder and CBT 66
  in children 284, 286, 288
epilepsy 46, 113
IQ 7, 297
life expectancy 264
offenders 297
sensory deficit 241
specialist services 253–255
minocycline 28, 34
MMR vaccination 182
mood disorders 43, 46, 47, 117, 171, 190–191
mood stabilisers 188
mortality 242, 265
naltrexone 187
neurexins 168, 183
neurodevelopmental disorders 11, 17, 154, 168, 169
  see also autism spectrum disorder (ASD)
neurodevelopmental syndromes 5, 6, 10, 17–19
neurofibromatosis 30
neurologicalis 168, 183
non-verbal communication 81, 134, 162
Noonan syndrome 30
normalisation movement 7
nosological overview 9–15
obsessive–compulsive disorder (OCD) 64, 65, 66, 166, 169, 191
occupational therapist: assessment 50
offending see forensic psychiatry
elder people see elderly people
opioid antagonists 136, 187
opossum–myoclonus (‘dancing eye’) syndrome 25–26, 32–33
PACT approach 84
pain 75–76, 247
parental inheritance and imprinting 29–30
parents: telling them child has disability 5, 251
pentoxifylline 182
personality disorder 96, 97, 165–166, 294
Personality Disorder: No Longer a Diagnosis of Exclusion 294
pfropfschizophrenie 44
phenylketonuria 6
phobias 64, 169
physical disabilities 14, 48
physical illness
  ASD 154
  behaviour problems 74, 75, 101
  psychiatric disorder 46–47
  see also health improvement; health screening
Picture Exchange Communication System (PECS) 81, 206
pivotal response training 211
polymerase chain reaction technology 29
polypharmacy 47, 77, 120, 168, 283
positive behaviour support 9, 82, 299–300
post-traumatic stress disorder (PTSD) 44, 65, 66, 92, 97
Prader–Willi syndrome
  aggression 34
  obesity 18, 25, 29–30, 242
OCD 64
  psychosis 18, 30
  skin picking 45–46, 76
  pregabalin 65
prenatal testing 8
prevalence of DID 16–19
primary care 243–244
  assessment 245, 255
  children 286, 287
  clinical competencies 246
  healthcare principles 255
  health checks 245, 255–256, 259
  linking with secondary care 249–263
  practice organisation 245
  practice registers 245, 255
  recall and audit 245
  recognition and knowledge 251
  referrals 251–252, 253–255, 258, 259
  resettlement from institutions 255
  roles of GPs 257
problem behaviours (PB) see behaviour problems
Psychiatric Assessment Schedule for Adults with Developmental Disabilities (PAS-ADD) 52, 61
psychiatric disorder 41–57, 301
  aetiology 45–49
  biological factors 45–47
  psychological factors 47–48
  social factors 48–49

311
INDEX

assessment 49–52
  behaviour problems 96
  of functioning 52–53
  multidisciplinary 50
  use of diagnostic instruments 50–52
behaviour problems and 73, 95–100, 101, 130
in children 277–290
diagnosis 52–53
epidemiology 41–45
  cohort effects 43
  prevalence and age 43
  prevalence and level of disability 43
  psychotic illness 44
  suicidality 45
  trauma 44
  in epilepsy 117–120
management 53–54
  capacity and consent 53
  medication 54
psychological 54
psychodynamic therapy 54
psychotropic treatment
ASD 201–235
  children 284, 288–289
  psychiatrist: assessment 50
psychologist: assessment 50
psychosis 47, 97
  ASD 159, 170–171, 192
  epidemiology 43, 44
  epilepsy 46, 118–120
  forced normalisation 119
  ictal 118–119
  inter-ictal 119
  post-ictal 118
Prader–Willi syndrome 18, 30
velo-cardio-facial syndrome 46
psychostimulants 189, 283
psychotropic medication 54
  aetiology of psychiatric disorder 47
  anxiety disorders 65–66
  ASD 34, 170–200, 301
  behavioural phenotypes 28, 34
  in children 283–284
  coordination of prescribing 259
  depression in elderly people 268
  polypharmacy 47, 77, 120, 181, 268, 283
  side-effects 77, 268, 283, 284
  see also individual drugs and drug types;
    psychotropic medication for behaviour
    problems
psychotropic medication for behaviour
problems 77–80, 82, 84, 89
in adults 130–144
  adverse events 134
  after prescribing 134–135
  assessment 131–132, 133, 139–141
  (Appendix 1)
  before prescribing 133–134
  case examples 141–142 (Appendix 2)
  concern about 130
  discontinuation of treatment 137–138
  during prescribing 134
  evidence base 135–137
  formulation 131–132, 133, 134
  general principles 131–132
  main recommendations 133–135
  national and international guidelines 131
  NICE guidelines 131, 132
  rating scales 134–135
  relapse plan 138
  treatment plan 134
  when to consider medication 132–133
rapamycin 34
Rasopathies 30
relaxation techniques 67, 125
Research Domain Criteria (RDoC) project 155
Rett syndrome 76
risperidone
  ASD 185–186, 187, 190, 191
  behaviour problems 130, 135, 137, 284
Rivo Autism Asperger Diagnostic Scale -
Revised (RAADS-R) 168
rubella encephalopathy 8, 31
safeguarding 292, 298
schizophrenia
  ASD 170–171, 183
  behaviour problems 96, 97
  epidemiology 43
  epilepsy 118, 119
  pfropfschizophrenie 44
  secondary impairments/disabilities 8, 15, 18
  secretin 181, 193
selective serotonin reuptake inhibitors
(SSRIs) 65, 137, 184–186, 191, 283
self-esteem 47–48
self-injurious behaviour (SIB) 33, 76, 96
  anxiety disorders 64–65
  ASD 76, 187–188, 209–210
  behavioural approach 82, 89
  genetic syndromes 18, 29, 76–77
  stress 89
INDEX

sensory deficit 241, 242–243, 284
serotonin–noradrenaline reuptake inhibitors (SNRIs) 65
service provision 239–304
for adults 255, 285–286
ageing in DID 264–276
behaviour problems 83–84
for children with mental health needs 277–290
continuity of care 258
epilepsy 126
forensic psychiatry 291–304
general health improvement 239–248
legal framework 261
linking primary and secondary care 249–263
models of service 255–260
teamwork concept 257–258
see also primary care; specialist services
severe intellectual disability 43
anxiety disorders 61
behaviour problems 72–73, 75, 81, 82, 96
in children 286, 288
epilepsy 46, 113
life expectancy 264
primary care 251, 286
sensory deficit 241
sexual abuse 298
'shutdown' responses 89
sleep disorders 77, 192
Smith–Magenis syndrome 18, 29, 52, 76–77
Snoezelen environment 67, 83
social factors
aetiology of psychiatric disorder 48–49
behavioural phenotypes 22, 23, 24
in children 280
social comparison 48
social support 48–49, 91, 172
social model: of disability 4, 5, 7, 8, 14, 15, 277
social phobia 64, 65, 67
social worker: assessment 50
sodium valproate 124–125, 136, 137
specialist services
access to 243–244
for children 285, 286, 287–288
linking primary and secondary care 253–255, 258
speech therapist: assessment 50
sterilisation, forced 7
suggestibility 298
suicidality 45, 49
systematic desensitisation 66
systemic model: of disability 4, 5–6
temporal lobe epilepsy 46, 118, 119, 121
terminology 3, 249–251, 284, 295
tic disorders 191
topiramate 124, 190
Tourette syndrome 191
toxic causes 30–31
trauma 44, 91–92, 97
trisomy 21: 6, 17, 26
tuberculosis 116, 148
Turner (XO) syndrome 29
uniparental disomy 18, 29
United Nations Convention on the Rights of Persons with Disabilities 8

Valuing People 8, 264
Valuing People Now 245
vancomycin 182
vascular dementia 272
velo-cardio-facial syndrome 46, 192
Vineland Adaptive Behavior Scales 11
vision impairment 241, 243, 266

Wechsler tests 7, 11, 282, 295–296
Welsh Health Check 245
Williams syndrome 18, 64
Winterbourne View 80, 302–303
written treatment plan 53